Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study

• DOI: 10.1177/03008916211037739
• Publication Date: 2021-08-07T11:21:53Z
• Authors: Ibrahim Cil; Ahmet Kucukarda; Muhammed Mustafa ...; Saban Secmeler; Nail Paksoy; Ferhat Ferhatoglu; Naziye Ak; Murat Ayhan; Deniz Tataroglu O...; Arif Hakan Onder; Okan Avci; Abdilkerim Oyman; Ilker Nihat Okten; Ilkay Gulturk; Baran Akagunduz; Tugba Basoglu; Emre Cakir; Ilhan Hacibekiroglu; Melike Ozcelik; Adnan Aydiner
• Keywords: Trastuzumab emtansine; Discontinuation

Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate and its survival advantage has been shown in advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, clinical trials underrepresent patients ⩾65 years of age, leading to a lack information this population. We analyzed the real-world outcomes older women who were treated with T-DM1 therapy.We performed multicenter, observational, retrospective analysis aged T-DM1. A total 93 from 10 cancer centers involved study. Our goal was determine survival, response rates, toxicity profile T-DM1-treated patients, as well factors that influence survival.Median follow-up 12.2 months. Objective rate 29%. Median progression-free (PFS) overall (OS) 8.47 15.0 months, respectively. In multivariate analysis, Eastern Cooperative Oncology Group Performance Score found be independent prognostic for worse PFS (hazard ratio [HR] 1.81, p = 0.032) OS (HR 2.33, 0.006). Any adverse event (AE) seen 92.5% patients; grade 3 or 4 AEs 30.1%. Dose reduction treatment discontinuation rates 11.8% 6.5%, respectively.The efficacy acceptable it generally well-tolerated among HER2-positive